The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 3-6 November 2014. Topics discussed at the meeting:
- PRAC recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)
- PRAC recommends further assessment of risk of developing inhibitors with Kogenate Bayer/Helixate NexGen
- PRAC advises informing about first case of PML in a patient treated with Tecfidera
Read PRAC's monthly report from the meeting 3-6 November 2014